Saros Therapeutics Inc Profile last edited on: 2/22/2024
CAGE: 9BJR9
UEI: HGU2SLP22BK2
Business Identifier: Developing, and through partnerships commercializing, novel immunotherapies to improve and extend the lives of patients with cancer. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Cook
Congr. District: 07
County: Cook
Public Profile
Developer of innate immune activation technology designed to enhance cancer immunotherapy. The company's technology combines with existing immunotherapies and has the potential to enable a safe and more effective immune response against the tumor than with immunotherapy alone.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $2,046,920 | |
| Project Title: Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation | ||||
Key People / Management
Matthew Martin -- Co-Founder and CEO
Richard Johnson -- Co-Founder, VP of Development
Dominique Kendrick -- Co-Founder Svp of Regulatory Affairs
James Moon -- Co-Founder Chief Scientific Officer
Richard Johnson -- Co-Founder, VP of Development
Dominique Kendrick -- Co-Founder Svp of Regulatory Affairs
James Moon -- Co-Founder Chief Scientific Officer
Company News
There are no news available.
